ImmunoGen, Inc.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase…
Biotechnology
US, Waltham [HQ]
Strategy & Leadership
Mergers & Acquisitions Beta
M&A Details · Industry · Urgent
M&A Deals · Breakdown
ImmunoGen, Inc. has no acquisition track records yet.
M&A Deals · History
ImmunoGen, Inc. has no acquisition track records yet.
M&A Deals · Within Industry
No current deals within Biotechnology Industry.
M&A Deals · Latest
Act, dont react; Track the most urgent M&A deals across all industries
Details
Details
Details
?
Equity
Agg. Maximum Price
$4,221.65
?
Details
Details
United Bankshares, Inc.
Equity
Agg. Maximum Price
$206,633,909.86
?
Details
Details
Details
Icahn Enterprises L.P.
Debt
Agg. Maximum Price
$700,000,000.00
?
Details
Details
Corebridge Financial, Inc.
Debt
Agg. Maximum Price
$500,000,000.00